UK life science competitiveness indicators 2022: measuring what matters most?
The latest life science competitiveness indicators (LSCIs) were published by the Office of Life Sciences (OLS) in July 2022. The indicators did not bring universal […]
NICE
NICE unlocks use of Amarin’s Vazkepa in 425k NHS patients
Health technology assessment (HTA) agency NICE has finalised its guidance on Amarin’s Vazkepa, clearing the path for GPs to start prescribing the drug in up […]
NICE backs two new breast cancer drugs for NHS use
Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer – Gilead’s Trodelvy and Novartis’ Piqray – […]
NICE makes J&J’s Tremfya more accessible in England and Wales
NICE has updated its recommendations for NHS use of Johnson & Johnson’s IL-23 inhibitor Tremfya in the treatment of psoriatic arthritis (PsA), expanding the pool […]
BMS’ Opdivo gets NHS use as adjuvant bladder cancer therapy
NICE has recommended routine use of Bristol-Myers Squibb’s Opdivo for the adjuvant treatment of some patients with urothelial carcinoma (UC), the most common form of […]
Lilly’s Verzenios gets NICE blessing for early-stage breast cancer
Thousands more people with breast cancer in England look set to be eligible for routine treatment with Eli Lilly’s Verzenios, after new guidance from NICE […]
Hansa gets NICE okay for Idefirix in kidney transplant patients
Sweden’s Hansa Biopharma has claimed a positive opinion from NICE for Idefirix, which becomes the first drug cleared for NHS use in a group of […]
Questions linger as England’s Innovative Medicines Fund kicks off
In part one of this two-article series on the latest on England’s Innovative Medicines Fund (IMF), Leela Barham examined what the IMF is and what […]
NICE backs Astellas’ oral therapy Evrenzo for anaemia in kidney disease
Astellas’ oral HIF-PH inhibitor Evrenzo has become the first drug in the class to be recommended for routine NHS use as a treatment for anaemia […]
NICE backs NHS use of Amarin’s Vazkepa for cardiovascular risk reduction
Around 425,000 in England and Wales with cardiovascular disease who are at risk of a secondary stroke or heart attack, could be eligible for treatment […]
NICE finds solution to making Keytruda available for TNBC
Around 100 patients in England and Wales with triple negative breast cancer (TNBC) that has spread to other parts of the body could soon access […]
Sleepio app for insomnia backed by NICE
After a non-committal appraisal of Big Health’s Sleepio app for insomnia last November in draft guidance from NICE, the cost-effectiveness agency has come out in […]
NICE endorses Magtrace diagnostic to detect breast cancer spread
Women with breast cancer in England and Wales will soon be able to access a new diagnostic based on an injectable magnetic marker liquid called […]
Gedeon Richter gets NICE nod for uterine fibroids drug Ryeqo
Around 4,500 women in the UK will be eligible for treatment with Gedeon Richter’s once-daily oral therapy Ryeqo, after NICE backed the GnRH antagonist to […]
NICE backs Biogen’s Vumerity for multiple sclerosis
Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen’s oral therapy Vumerity, after NICE recommended the […]
UK launches its ‘Netflix-style’ payment model for antibiotics
The UK is poised to become the first country in the world to launch a new payment model for antibiotics that could reverse decades of […]
NICE verdict on Trodelvy threatens unequal access to drug in UK
In draft guidance, NICE has said it cannot recommend Gilead Sciences’ Trodelvy in triple-negative breast cancer (TNBC), setting up a disparity in access to the […]
NICE reverses stance on Merck’s Bavencio for bladder cancer
Last year, NICE said that Merck KGaA/Pfizer’s Bavencio was too expensive for routine in NHS use as a first-line maintenance treatment for bladder cancer, even […]
NICE expands access to real-time glucose monitoring for diabetics
More than 250,000 people living with type 1 diabetes in the UK will be offered real-time continuous glucose monitoring (CGM) technology, reducing their reliance on […]
NICE firms up NHS use of Vimizim for Morquio A syndrome
In 2015, NICE said that BioMarin’s Vimizim could be used to treat patients with the ultra-rare disease Morquio A syndrome, while real-world data was collected […]
NICE says no to Keytruda in triple-negative breast cancer
There isn’t enough evidence to support the use of Merck & Co/MSD’s Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative […]
NICE’s new Severity Adjustment
In the United Kingdom, the National Institute for Health and Care Excellence (NICE) made an update to their health technology evaluations manual in January 2022. […]
GSK’s ZEJULA gets green light for NHS use
The UK’s National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal […]
GSK’s ZEJULA gets green light for NHS use
The UK’s National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal […]
Novo Nordisk gets NICE okay for obesity drug Wegovy
Novo Nordisk’s new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients […]
How does rare disease prevalence impact drug pricing in England?
In this second article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discusses the role that disease rarity plays in […]
NHS signs deal with Orchard for pricey Libmeldy gene therapy
NHS England has agreed a confidential deal with Orchard Therapeutics that will allow access to Libmeldy – a gene therapy for a rare childhood disease […]
NICE expands cover for AZ’s high potassium drug Lokelma
NICE has recommended extending funding via the NHS for AstraZeneca’s elevated potassium therapy Lokelma in new guidance, making it easier to receive the drug outside […]
After a Scottish aye, NICE says no to Lynparza for prostate cancer
AstraZeneca’s PARP inhibitor Lynparza should not be made available routinely on the NHS n England and Wales as a treatment for prostate cancer, according to […]
NICE backs Aimmune’s peanut allergy drug Palforzia for children
Children in England with peanut allergies could be among the first in Europe to get access to Aimmune’s oral immunotherapy Palforzia, after the drugmaker agreed […]
2021 in review: Building the framework of a patient-centric industry
Patient centricity and patient engagement have been hot topics in pharma for some time – but buzz words do not always translate into concrete action. […]
Samantha Roberts to replace Gillian Leng as CEO of NICE
Prof Gillian Leng’s replacement as chief executive of the National Institute for Health and Care Excellence (NICE) has been named as Dr Samantha Roberts, currently […]
NICE gives Keytruda parity with Opdivo for adjuvant melanoma
After three years of availability via the Cancer Drugs Fund (CDF), MSD’s checkpoint inhibitor Keytruda has now been approved for routine NHS use after surgery […]
After Scotland says no, NICE backs Lilly’s Retsevmo for lung cancer
Eli Lilly’s RET inhibitor Retsevmo can now be prescribed on the NHS for people with RET fusion-positive advanced non-small cell lung cancer (NSCLC) in England […]
UK-wide whole genome sequencing for newborns is feasible – but there are some key questions to answer first
Genomics England, the Department of Health and Social Care’s genome-sequencing hub, has this year announced that support for whole genome sequencing (WGS) has reached a […]
Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy
Shots: NICE has issued a positive Final Appraisal Document which recommends Sunosi (75/150mg, qd) as an option treatment for adults with EDS caused by narcolepsy […]
NICE reaches a deal with Roche on access to oral SMA drug Evrysdi
Roche’s oral treatment Evrysdi for the rare genetic disease spinal muscular atrophy (SMA) will be made available on the NHS in England, after NICE reached […]
NICE backs ViiV/J&J’s six-per-year injection for HIV
People living with HIV in England and Wales now have an alternative to daily oral tablets, after NICE backed NHS use of two long-acting injectable […]
NICE changes tack on NHS use of BMS’ myelofibrosis drug Inrebic
After turning down routine NHS funding of Bristol-Myers Squibb’s Inrebic for bone marrow disorder myelofibrosis earlier this year, NICE now says the drug can be […]
Drug-resistant epilepsy drug Ontozry backed by NICE
NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini […]
NICE changes tack on ‘game changer’ rare cancer therapy Poteligeo
NICE has reversed an earlier decision not to recommend NHS use of Kyowa Kirin’s Poteligeo for two rare blood cancers, ending the threat of a […]
Cautious welcome as NICE backs Forxiga for chronic kidney disease
Tens of thousands of people with chronic kidney disease in England could be eligible for treatment with AstraZeneca’s SGLT2 inhibitor Forxiga, after NICE backed NHS […]
NICE uncertain on insomnia app Sleepio in draft guidance
Big Health’s Sleepio app for insomnia has been cautiously backed by NICE in preliminary guidance, although the cost-effectiveness agency says more data on longer-term use […]
Seagen’s breast cancer drug Tukysa turned down by NICE
NICE has decided not to recommend Seagen’s orally-active HER2 inhibitor Tukysa for advanced breast cancer in draft guidance, saying it isn’t a cost-effective use of […]
Alnylam gets NICE backing for porphyria therapy Givlaari
UK cost-effectiveness watchdog NICE is set to recommend NHS use of Alnylam’s gene-silencing therapy Givlaari in England and Wales for the rare disease acute hepatic […]
Sanofi’s Dupixent (dupilumab) Receives NICE Recommendation for the Treatment of Severe Asthma
Shots: The NICE has issued a final appraisal determination (FAD) which recommends Dupixent (dupilumab) as an add-on maintenance treatment for severe asthma The NICE recommendation […]
A test of NICE’s resolve: clinical guidelines for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
The work of the UK’s HTA body, the National Institute for Health and Care Excellence (NICE), is often heatedly debated, and this time it’s for […]
NICE changes stance on Sanofi’s Dupixent for severe asthma
18 months after saying “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed […]
What does the future of European healthcare look like?
After the “stress test” of COVID, how can the sector create resilient, sustainable healthcare systems for the long term? COVID has taught us that future […]
Consternation as NICE rejects Janssen MS drug Ponvory
NICE has delivered its first verdict on NHS funding of Janssen’s oral multiple sclerosis drug Ponvory, and it’s not good news for patients with the […]
Novartis’s Adakveo (crizanlizumab) Receives NICE Recommendation as a New Therapy for Sickle Cell Disease
Shots: The NICE has recommended Novartis’ Adakveo (crizanlizumab) as a new treatment option to prevent recurrent sickle cell crises in patients aged ≥16 Additionally, patients […]
Joy as sickle cell patients get access to Novartis’ Adakveo after NICE ruling
People living with sickle cell disease (SCD) in England and Wales will be able to get access to treatment with Novartis’ Adakveo, thanks to a […]
NICE clears NHS use of Roche’s Tecentriq in bladder cancer
NICE has recommended routine NHS access to Roche’s cancer immunotherapy Tecentriq for some bladder cancer patients, four years after it was first made available via […]
Keytruda backed by NICE for late-stage oesophageal cancer
MSD’s Keytruda has become the first immunotherapy cleared by NICE for previously-untreated patients with advanced oesophageal cancer, making it an option for routine NHS treatment. […]
NICE backs BioCryst’s Orladeyo for hereditary angioedema
BioCryst Pharma’s Orladeyo has been recommended by NICE as a treatment for the rare disease hereditary angioedema (HAE) in England, Wales and Northern Ireland. Orladeyo […]
NICE changes its mind on J&J’s Erleada in prostate cancer
NICE has reversed its position on Johnson & Johnson’s oral prostate cancer therapy Erleada in patients with hormone-relapsed or hormone sensitive tumours, backing NHS use […]
NICE backs Cosentyx’ use in thousands of children with psoriasis
NICE has recommended broadening NHS use of Novartis’ IL-17 inhibitor Cosentyx to include children aged six to 17 with severe plaque psoriasis. The cost-effectiveness agency […]
NICE backs NHS use of Novartis’ cholesterol drug Leqvio
Novartis’ cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help to prevent up to 30,000 deaths, according […]
NICE rejects J&J’ Darzalex regimen for multiple myeloma
New guidance from NICE has rejected a combination regimen based on Johnson & Johnson’s Darzalex for a group of previously-untreated patients with multiple myeloma, a […]
NICE says yes to Novartis’ Rydapt for rare blood disorder
Novartis’ Rydapt has become the first and only licensed treatment for rare and life-threatening blood disorder systemic mastocytosis (SM) to be cleared for routine NHS […]
A problem combination?
Leela Barham takes stock of past NICE decisions for combinations to explore the scale of the reimbursement challenge for combination therapies. Combination therapies are now […]
NICE changes stance on Lilly’s breast cancer dug Verzenio
After rejecting Eli Lilly’s Verzenio for breast cancer therapy earlier this year, NICE has relented, recommending the drug for routine NHS use alongside hormonal therapy […]
Scotland backs Bavencio for bladder cancer after NICE says no
Patients with bladder cancer in Scotland will be the first in the UK to claim access to maintenance treatment with Merck Serono and Pfizer’s Bavencio, […]
How to balance the patient voice atop the shifting plates of HTA
The tectonic plates of healthcare technology assessment (HTA) have shifted – but where does the patient voice fit within this new evaluation paradigm? Recent advances […]
UCB’s bimekizumab ‘pre-approved’ using NICE fast-track scheme
UCB’s bimekizumab hasn’t been approved for marketing in Europe yet, but has already been given the nod for NHS use in England and Wales under […]
NICE changes its mind on rare bile duct cancer drug from Incyte
Incyte’s Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer, after NICE concluded it provided value for […]
NICE second Zytiga rejection ‘shows need for flexible pricing models’
NICE has stuck with its original decision to reject NHS funding for Johnson & Johnson’s Zytiga as a treatment for men with newly diagnosed advanced […]
NICE feedback?
The National Institute for Health and Care Excellence (NICE) is quite far along a NICE-led process to review its methods and processes for evaluating technologies. […]
NICE rejects Orchard’s gene therapy for rare childhood disease MLD
Orchard Therapeutics’ gene therapy for rare childhood disease metachromatic leukodystrophy (MLD) Libmeldy has been rejected for NHS use by NICE in draft guidance. The agency […]
NICE backs Novartis’ Cosentyx for underdiagnosed back condition
NICE has extended the range of indications that Novartis’ Cosentyx can be prescribed for by the NHS in England, giving a green light for its […]
Artificial pancreas will be piloted in 1,000 diabetics, says NHS CEO
NHS England will provide artificial pancreas devices to 1,000 type 1 diabetes patients as part of a pilot study of the technology, according to chief […]
How the patient voice is becoming vital for drug approval
Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores […]
Time for a NICE change
The National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and cost-effectiveness of new treatments. In recognition of […]
NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient group
NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a […]
NICE rejects J&J’s prostate cancer drug Erleada in initial guidance
NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance. The […]
How will NICE fare in a post-Brexit world?
NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Experts […]
NICE says final ‘no’ to BMS’ Zeposia for multiple sclerosis
NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a decision that prevents access for patients in England and […]
NICE says ‘no’ to Pfizer’s Vyndaqel for rare heart condition
NICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has left the door open for negotiations if […]
NICE’s Office for Digital Health opens its doors
UK cost-effectiveness agency NICE has this week officially opened the Office for Digital Health, one of the pillars of its five-year strategy out to 2026. […]
Patients in England get fast access to AZ’s Tagrisso in early lung cancer
The UK’s drugs regulator has swiftly granted a licence extension for AstraZeneca’s Tagrisso in certain patients with early stage lung cancer, with NICE allowing fast […]
Deep Dive: Market Access
It’s fair to say this is the most interesting time ever for market access. Not only has COVID forced companies, governments and healthcare systems to […]
The next five years of NICE: Challenges, opportunities, and the future of technology assessment
If NICE is to remain a “beacon of evidence-based medicine”, it must become more agile, more flexible, and more ready to adapt – and COVID-19 […]
Enhertu cleared for NHS use via Cancer Drugs Fund
NICE has recommended the use of AstraZeneca and Daiichi Sankyo’s Enhertu in draft guidance, the first time the drug has been commissioned in any European […]
NICE unveils five year plan promising faster access to medicines
NICE has included proposals to speed up evaluations and focus on new technology such as digital health in a new strategy to provide faster access […]
NICE unveils five year plan promising faster access to medicines
NICE has included proposals to speed up evaluations and focus on new technology such as digital health in a new strategy to provide faster access […]
NICE recommends Alexion’s long-acting Ultomiris for PNH
NICE has recommended Alexion’s long-acting Ultomiris (ravulizumab) for the rare disease paroxysmal nocturnal haemoglobinuria (PNH) in final draft guidance. Ultomiris is Alexion’s follow-up to its […]
NICE backs Sobi’s Kineret for rare inflammatory disease
The UK’s cost-effectiveness agency NICE has recommended that Sobi’s Kineret can be used to treat NHS patients with Still’s disease, a rare form of arthritis […]
NICE methods and process review aims to create fertile ground for innovation
The way NICE reviews new medicines is about to go through its biggest change in years – but what do the proposals mean for the […]
NICE backs ovarian cancer and multiple myeloma combination drugs
NICE has recommended funding for two cancer drug combinations for ovarian cancer and multiple myeloma. In final draft guidance that applies to England, NICE said […]
NICE backs ovarian cancer and multiple myeloma combination drugs
NICE has recommended funding for two cancer drug combinations for ovarian cancer and multiple myeloma. In final draft guidance that applies to England, NICE said […]
NICE says NHS should fund Novartis’ £1.79m SMA gene therapy
The NHS should pay for Novartis’ £1.79 million one-off gene therapy for Spinal Muscular Atrophy (SMA) NICE has said, the most expensive treatment ever approved […]
NICE says no to AZ’s Lynparza for prostate cancer
NHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they have BRCA-positive advance prostate cancer, according to […]
Lilly’s Olumiant is first JAK drug backed by NICE for eczema
Eli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended for NHS use in England and Wales […]
NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali
NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final […]
bluebird bio ‘baffled’ after NICE rejects beta-thalassaemia gene therapy
It’s back to the drawing board for bluebird bio and its discussions with NICE, which has rejected its beta thalassaemia gene therapy Zynteglo for regular […]
NICE backs NHS funding for MSD’s Keytruda combination in lung cancer
NICE has backed regular NHS funding England and Wales for Merck, Sharp and Dohme’s Keytruda in combination with pemetrexed and platinum chemotherapy in certain lung […]
UK patient group warns COVID could limit access to Novartis’ new eye drug
NICE has recommended regular NHS funding for Novartis’ long-acting eye drug Beovu (brolucizumab) in England and Wales – but a patient group warned that access […]
NICE reverses stance on Celgene’s Revlimid for myeloma maintenance
NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance […]
Unlocking health data to improve oncology outcomes
As the largest single-payer healthcare system in Europe, the UK’s National Health Service (NHS) has a uniquely beneficial health data and real-world evidence (RWE) environment. […]
NICE backs broad use for Gilead/Galapagos arthritis pill Jyseleca
Patients with rheumatoid arthritis (RA) in England will be able to get treatment with Gilead Sciences and Galapagos’ JAK inhibitor Jyseleca, after it was backed […]
NHS and Kite sign access deal for Kite’s cancer cell therapy Tecartus
NHS patients in England will be among the first in the world to receive Gilead’s Tecartus cancer cell therapy for certain types of lymphoma, after […]
NICE recommends interim funding for GSK’s Zejula in ovarian cancer
Women with newly-diagnosed advanced ovarian cancer have a new treatment option in England after NICE recommend interim funding for GlaxoSmithKline’s Zejula (niraparib) in final guidance. […]
2021 – UK market access prospects
With a new year comes the opportunity to think ahead for the market access landscape for the coming year. 2020 was a big year for […]
Unconvinced by NHS test run, NICE rejects BMS’ Opdivo in head and neck cancer
NICE has rejected Bristol Myers Squibb’s immunotherapy Opdivo as a second-line treatment for head and neck cancer in first draft guidance, unconvinced by evidence unearthed […]
NICE backs AZ’s Forxiga for heart failure
Just a few weeks after its EU approval for heart failure, AstraZeneca’s Forxiga has been backed by NICE for this use by the NHS in […]
CLL patients in England to get AZ’s Calquence after okay from NICE
NHS England is to grant immediate access to AstraZeneca’s cancer drug Calquence (acalabrutinib) for certain patients with chronic lymphocytic leukaemia (CLL) after NICE backed it […]
iRhythm digital heart monitoring service backed by NICE
A heart monitor developed by iRhythm has become the first product to be endorsed by NICE in a pilot project covering digital health technologies. In […]
NICE says yes to Braftovi combination for colorectal cancer
Two months after rejecting Pierre Fabre’s Braftovi for a rare form of metastatic colorectal cancer (mCRC), NICE has changed its mind, and now says the […]
NICE backs Lilly’s Emgality for migraine, adding pressure on Novartis rival
UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the […]
Vertex Pharma’s vision for reimbursement innovation
As regional vice president for Northern Europe & Australia, Simon Lem led the digital launch of Vertex Pharma’s novel cystic fibrosis drug Kaftrio. He tells […]
NICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drug
Previously-untreated patients with hepatocellular carcinoma (HCC), a common form of liver cancer, will have an immunotherapy-based treatment option after NICE gave the nod to NHS […]
After two decades, NICE begins consultation on drug assessment methods
The UK’s drug cost-effectiveness body NICE has launched a public consultation, presenting the case for change about how it assesses medicines, medical devices and diagnostics. […]
Price cut leads NICE to back Novo Nordisk’s obesity drug Saxenda
Novo Nordisk’s Saxenda has been recommended by NICE as a treatment for obesity, ending a 10-year drought in new drug therapies for weight management. The […]
NICE talking to you: Trends in early HTA engagement
With exclusive data from Freedom of Information (FOI) requests sent to the National Institute for Health and are Excellence (NICE), Leela Barham takes a look […]
NICE changes stance on Keytruda for first-line head and neck cancer
As recently as June, NICE was minded not to back routine NHS of MSD’s Keytruda as a first-line treatment for advanced head and neck cancer, […]
Sanofi’s Sarclisa (isatuximab) Receives NICE Recommendation for Patients with Multiple Myeloma
Shots: The NICE has issued FAD which is based on the P-III ICARIA-MM trial assessing isatuximab + pom-dex vs pom-dex in patients prior treated with […]
Lilly to buy private biotech Disarm Therapeutics for up to $1.36bn
Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a […]
NICE changes its mind on Novartis’ progressive MS drug Mayzent
UK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down earlier this year in draft guidance. The […]
NICE recommends regular NHS funding for Roche’s lymphoma drug Polivy
NICE has recommended regular NHS funding for Roche’s Polivy in certain lymphoma patients in final draft guidance, overturning a previous rejection. The new guidance recommends […]
How does HTA for orphan drugs differ across europe?
New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines across Europe. Rare diseases drugs have always […]
NICE backs kidney cancer combination from Merck KGaA and Pfizer
NICE has said a combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta should be available as a first line option for kidney cancer patients for […]